Page last updated: 2024-11-07

n-hydroxysuccinimide suberic acid ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

disuccinimidyl suberate: used as protein cross-linking agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100658
SCHEMBL ID37833
MeSH IDM0135399

Synonyms (49)

Synonym
68526-60-3
einecs 271-216-2
nsc340008
68528-80-3
nsc-340008
2, 1,1'-[(1,8-dioxo-1,8-octanediyl)bis(oxy)]bis-
disuccinimidyl suberate
suberic acid bis(n-hydroxysuccinimide ester), >=95%, powder
di(n-succinimidyl) octanedioate
octanedioic acid di(n-succinimidyl) ester
D3895
suberic acid di(n-succinimidyl) ester
di(n-succinimidyl) suberate
n-hydroxysuccinimide suberic acid ester
bis(2,5-dioxopyrrolidin-1-yl) octanedioate
1,1'-((1,8-dioxo-1,8-octanediyl)bis(oxy))bis-2,5-pyrrolidinedione
dsis
nhs-sa
2,5-pyrrolidinedione, 1,1'-((1,8-dioxo-1,8-octanediyl)bis(oxy))bis-
nsc 340008
FT-0641189
suberic acid bis(n-hydroxysuccinimide ester)
disuccinimidyl octanedioate
FT-0625348
AKOS015915589
SCHEMBL37833
mfcd00049059
c16h20n2o8
disuccinimidylsuberate ,
dss crosslinker
BP-22656
2,5-pyrrolidinedione, 1,1'-[(1,8-dioxo-1,8-octanediyl)bis(oxy)]bis-
1,8-bis(2,5-dioxo-1-pyrrolidinyl)ester octanedioic acid
GS-6316
dss (chemical shape indicator)
Q3885907
suberic acid bis(n-hydroxysuccinimide*ester)
(dss);disuccinimidyl suberate
DTXSID70988200
1,1'-[(1,8-dioxooctane-1,8-diyl)bis(oxy)]di(pyrrolidine-2,5-dione)
BCP29489
dss crosslinker (disuccinimidyl suberate)
A867024
octanedioic acid bis-(2,5-dioxo-pyrrolidin-1-yl) ester
bis(2,5-dioxo-1-pyrrolidinyl) octanedioate
SY057274
CS-0030444
HY-W019543
H10374

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Transdermal administration of drugs improves their bioavailability and is capable of systemic and local treatment."( Transdermal delivery of 40-nm silk fibroin nanoparticles.
Hattori, K; Inagi, T; Kakami, Y; Kameda, T; Makino, K; Miura, S; Okumura, M; Shimamura, Y; Shirai, H; Takeuchi, I; Terada, H, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" This preparation produced a dose-response curve in the presence of active cardiotoxin and demonstrated that cardiotoxin retained its biological activity after boiling, although cardiotoxin activity was destroyed by heating in the presence of dithiothreitol."( A bioassay for cobra cardiotoxin activity using semi-isolated cockroach heart.
Klowden, MJ; Trumble, MJ; Trumble, WR; Vitale, AJ; Wesson, CR, 1992
)
0.28
" For both CSFs specificity of formation of cross-linked species was demonstrated by showing that the homologous unlabeled CSF (but not other CSFs) competed for formation of the complexes with the appropriate dose-response relation, by showing that saturation occurred over the appropriate range of 125I-CSF concentration and by showing that the cellular specificity of CSF binding paralleled that for cross-linked complex formation."( Identification of distinct receptors for two hemopoietic growth factors (granulocyte colony-stimulating factor and multipotential colony-stimulating factor) by chemical cross-linking.
Nicola, NA; Peterson, L, 1986
)
0.27
" Finally, the dose-response curves for the inhibition of binding of 125I-C5a by unlabeled C5a and the inhibition of cross-linking are similar."( Identification of the polymorphonuclear leukocyte C5a receptor.
Rollins, TE; Springer, MS, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (268)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990106 (39.55)18.7374
1990's112 (41.79)18.2507
2000's27 (10.07)29.6817
2010's19 (7.09)24.3611
2020's4 (1.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.85 (24.57)
Research Supply Index5.61 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.37%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other270 (99.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]